UNSPSC 51362203: Carfimate

This classification denotes a sedative and hypnotic with the molecular formula C10H9NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X9N1XKR2OS, chemically known as carbamic acid, 1-phenyl-2-propynyl ester but generally known as carfimate, which bears US NIH Compound Identifier 19111. European Medicines Agency schedules Carfimate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06627MIG. The term CARFIMATE is an International Non-Proprietary Name.

UNSPSC 51362203 Carfimate is a Commodity code under which state and local governments procure pharmaceutical products and drug-related public health supplies, including naloxone, over-the-counter medications, and generic pharmaceuticals distributed through established wholesaler networks and direct-to-manufacturer channels. Recent solicitations show state and local health agencies buying naloxone and drug deactivation systems for community health initiatives, generic pharmaceutical supplies for multi-state cooperative purchasing programs, and exploring direct-to-manufacturer prescription fulfillment models to reduce intermediary costs and improve supply chain efficiency. The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances; Seminole County, Florida and the Minnesota Department of Administration have issued recent opportunities under this code, with the Texas Health and Human Services Commission conducting exploratory market research on direct pharmacy procurement models.

Recent activity clusters in Florida and Minnesota, with secondary engagement from Texas. Seminole County, Florida issued IFB60459723LAS on June 30, 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building, with bids due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP posted January 20, 2026 for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with responses due March 26, 2026 and contract awards effective July 1, 2026; the RFP weights price competitiveness at 75 percent and requires compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, and minimum insurance coverage of $5 million commercial general liability. The Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, with responses due April 3, 2026, signaling state interest in alternative pharmaceutical supply models.